June 25, 2003

ATTN: Medical Health Officers and Branch Offices
     Public Health Nursing Administrators and Assistant Administrators
     Holders of Communicable Disease Control Manuals

Re: Revisions to the Immunization Program Chapter of the
    Communicable Disease Control Manual

Please note the following revisions to the Immunization Program Chapter:

(1) Section I: Introduction –

• Table of Contents: the page numbers for this section of the Manual are
  updated.

• Page 9, Section 7.0 “History of Immunization Development in BC”: added
  the pneumococcal conjugate and meningococcal C conjugate vaccines

• Pages 10 –12: page dates updated to reflect repagination.

• Page 15: meningococcal and pneumococcal diseases added to Table 1:
  Relative Risks of Disease and Immunization.

• Page 16: Vaccine Effectiveness: meningococcal and pneumococcal
  conjugate and polysaccharide vaccines added to table.

Administrative Circular # 2003:09
(2) **Section II: Immunization Schedules** –

- Table of Contents: the page numbers for this section of the Manual are updated.

- Page 1, Section 1.0 “Guidelines for Immunization Schedules”: For clarity, two separate bullets created to deal with vaccine dosage. One bullet addresses smaller than recommended dosages, and the next addresses larger than recommended dosages.

- Page 6, Section 3.0: this section is now “Vaccines Recommended for High Risk Clients”.

- Page 7: new chart indicates vaccines recommended for high risk clients.

- Page 8, Section 4.0: “Schedule A: Basic Immunization”: pneumococcal conjugate and meningococcal C conjugate added to the basic immunization schedule.

- Page 9: Hib Schedule table moved from previous page.

- Page 10, Section 5.0 “Schedule B: Children 1 year and over but < 7 years when starting immunization”: Meningococcal C conjugate vaccine for infants born on or after July 1, 2002 added to this schedule.

- Page 11, Section 6.0 “Schedule C: Children 7 to 18 years (inclusive) when starting immunization”: schedule revised to reduce the number of clinic visits; Meningococcal C conjugate vaccine added at grade 6, starting in the 2003/2004 school year.

- Pages 12 – 13: page dates reflect repagination.

(3) **Section III: Contraindications and Routine Precautions for Immunization** –

- Table of Contents: the page numbers for this section of the Manual are updated.

- Page 2, sub-section 4.1 is now “Latex allergy”. For clients with a history of an anaphylactic reaction to latex, vaccines supplied in vials or syringes that contain dry natural rubber should not be administered, unless the benefits of vaccination outweigh the risk of an allergic reaction.

- Page 3 date change reflects repagination.
• Page 8, sub-section 8.1: “Major neurological disorders”: the phrase “consult with attending doctor” deleted.

• Page 12, sub-section 8.10 “Splenic disorders”: *Neisseria meningitidis* added to list of encapsulated bacteria. Meningococcal conjugate C vaccine added to this section, and reference to residence in or travel to endemic areas deleted.

• Page 15, sub-section 8.14 “Adult and child immunization post hematopoietic stem cell transplant (HSCT)”: Meningococcal C conjugate vaccine and pneumococcal conjugate vaccine added to list of vaccines supplied free to this group.

• Page 16: new chart outlines the scheduling of vaccines to be administered to HSCT clients. Clients will present at health units with this schedule and a letter from their treating physician.

• Pages 17 – 18: page dates reflect repagination.

(4) **Section IV: Vaccine Administration** –

• Table of Contents: the page numbers for this section of the Manual are updated.

• Page 14: a new subsection has been added, 9.0: “Considerations for the Administration and Scheduling of Multiple Injections.”

• Pages 15 – 16: page dates reflect repagination.

(5) **Section V: Anaphylaxis** -

• Page 3: deleted bullet that referred to Table 2 (which had been deleted in the previous revision).

• Page 4: revised wording in last bullet: "give oral Benadryl®….if the client is conscious and able to swallow because…"

(6) **Section VII: Biological Products** –

• Table of Contents: the page numbers for this section of the Manual are updated.

• Page 13 “Hepatitis B Post-Exposure Prophylaxis for Percutaneous and Mucosal Exposures ”- this page is consistent with the April 2003 revisions to the Blood and Body Fluid Exposure Management Guidelines.
• Page 15: "Hepatitis B Vaccine for Students of Health Care Professions" – Embalmers and Funeral Directors have been added to this list.

• Page 24: "Hepatitis A and B Vaccine Combined “- Alignment of information under “reinforcements” has been corrected.

• Pages 29 and 30: changed the timing for administration of live virus vaccines after IVIG treatment of Idiopathic Thrombocytopenic Purpura or Kawasaki Disease to 11 months, and after RSV IGIV to 9 months. This timing is consistent with Canadian Immunization Guide Recommendations.

• Pages 35 and 36: “Meningococcal C Conjugate Vaccine (Menjugate®);” and pages 37 and 38: “Meningococcal C Conjugate Vaccine (Neis Vac-C)”

  - Under “Initial Series,” “Age at presentation” has been added.
  - Under “Precautions” for Menjugate™, deleted statement “There is no information on co-administration of Menjugate™ with hepatitis B-containing vaccines”.
  - Under "Routine Indications" for Neis Vac-C, added "infants born on or after July 1, 2002.
  - Under "Precautions " for Neis Vac-C, deleted statement “There is no information on co-administration of Neis Vac-C with hepatitis B-containing vaccines”.
  - New footnote ♥ “If series is interrupted, complete series according to age at which child re-presents.”

• Page 39: “Meningococcal Polysaccharide Vaccine (Menomune®)” -

  - Deleted footnote ♠
  - Amended Note – “Once reconstituted…multidose must be used within 35 days”.

• Page 40: “Meningococcal Polysaccharide Vaccine (Menomune®)” -

  - Added Note – “Once reconstituted…multidose must be used within 35 days”.

• Page 41: “Pneumococcal Conjugate Vaccine (Prevnar™)” -

  - Under "Indications:" added "Infants born on or after July 1, 2003 - starting at 2 months of age."
  - Booster dose is to be given at 18 months of age.
• Clarified scheduling information for children 24 to 59 months of age. Healthy children receive one dose of Prevnar™; high risk children as specified in "Indications: (2)" receive 2 doses.

• Page 42: Added ♣ footnote to clarify which individuals are eligible for once-only revaccination with PPV 23

• Page 53: Tetanus-Diphtheria-acellular Pertussis (TdaP) (Adacel™) - new footnote elaborating on the number of doses to administer according to prior immunization history with a pertussis-containing vaccine.

• Page 63: “Varicella Vaccine (Varivax® III) –

• Inserted “≥” 13 years of age, which had been omitted previously.

• Page 65: new page added, Dukoral™ (oral, inactivated travelers’ diarrhea and cholera vaccine).

Please remove and destroy the following from the Immunization Chapter of the Communicable Disease Control Manual:

Section I, Table of Contents
Pages 9,10,11,12,15 and 16       Dated November 2002

Section II, Table of Contents
Pages I, 6, 9, 11       Dated November 2002
Pages 7, 8, 10       Dated March 2003

Section III, Table of Contents
Pages 8, 15 and 17       Dated March 2003
Pages 2, 3,12 and 16       Dated November 2002

Section IV, Table of Contents
Pages 14, 15 and 16       Dated November 2002

Section V
Pages 3 and 4       Dated June 2003

Section VII, Table of Contents
Pages 15, 29 and 30       Dated November 2002
Pages 13, 24, 35, 36, 37, 38, 39, 40, 42, 53 & 63       Dated March 2003
Page 41       Dated April 2003

Please insert the following pages, dated June 2003:

Section I: TOC, pages 9, 10,11,12, 15 and 16
Section II: TOC, pages 1, 6, 7, 8, 9, 10, 11, 12 and 13

Section III: TOC, pages 2, 3, 8, 12, 15, 16, 17 and 18

Section IV: TOC, pages 14, 15, 16

Section V: Pages 3 and 4

Section VII: TOC, pages 13, 15, 24, 29, 30, 35, 36, 37, 38, 39, 40, 41, 42, 53, 63 and 65.

If you have any questions or concerns, please contact Karen Pielak, Nurse Epidemiologist or Cheryl McIntyre, Associate Nurse Epidemiologist at (604) 660-6061 or email karen.pielak@bccdc.ca or cheryl.mcintyre@bccdc.ca

Yours sincerely,

David Patrick
Director
Epidemiology Services
BC Centre for Disease Control

DMP/kka

pc:    Dr Perry Kendall                         Dr. Shaun Peck
       Provincial Health Officer                 Deputy Provincial Health Officer
       Ministry of Health Services               Ministry of Health Services

Dr. Bob Fisk                            Lorna Storbakken
Medical Consultant                      Director
Non-Communicable Disease Services       Disease and Injury Prevention Branch
Ministry of Health Planning

Jane Crickmore                           Ministry of Health Planning
Public Health Nursing Consultant        Branch
Disease and Injury Prevention Branch
Ministry of Health Planning